Posted in Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotech, Celgene, Daiichi Sankyo, FDA, Forest Labs, GSK, Genentech, J&J, Johnson and Johnson, Lilly, Medical Devices, Medicine, Merck, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Red Cross, Sales training, Sanofi-Aventis, Statins, Takeda, tagged alimta, asco, Avastin, herceptin, Millennium, psoriasis, rad001, ranbaxy, s, trasylol, vaptan, vectibix, viagra, xience, zometa on May 16, 2008 | No Comments »
There’s a ton of stuff going on this week, plus we’re in pre-ASCO mode (so lots of oncology news - scroll down for those headlines). Here we go:
What’s a vaptan? Maybe something pretty exciting - A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, [...]
Read Full Post »
Posted in Bayer, Lilly, Merck, News, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, tagged cholesterol, diuretic, Galvus, Nexavar, Statins on February 1, 2008 | No Comments »
After all that effort with alpha-blockers, beta-blockers, ACE inhibitors, etc….are we just going to circle back to diuretics??
Will Eli Lilly fork over $1,000,000,000 to make Zyprexa marketing headaches go away?
More on the statin question - do statins really prolong life? And more on whether cholesterol matters.
Bayer’s Nexavar - looking promising for leukemia (AML).
Novartis‘ Galvus gets [...]
Read Full Post »
Posted in AstraZeneca, Bayer, Biotech, Celgene, Cephalon, Daiichi Sankyo, FDA, Forest Labs, GSK, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Merck, Novartis, Pharma News, Pharmaceutical, Sanofi-Aventis, Schering, tagged alzheimers, Biogen-Idec, Celgene, Eisai, Gleevec, MGI Pharma, Mylan, prasugrel, revlimid, taurel, Treanda, tykerb, Velcade, vytorin, Zevalin on December 18, 2007 | No Comments »
Some interesting oncology results:
Millennium’s Velcade used in combo therapy for multiple myeloma shows impressive results.
Cephalon’s Treanda shows impressive remission numbers for CLL, and effectiveness in non-Hodgins lymphoma (NHL).
Celgene’s Revlimid continues to produce good results at a low-dose regimen.
Novartis‘ Gleevec: effective at halting leukemia progression up to 6 years.
Eisai decides to grab MGI Pharma, and its [...]
Read Full Post »
Posted in BMS, Bayer, Cephalon, Daiichi Sankyo, FDA, Healthcare, J&J, Johnson and Johnson, Lilly, Pfizer, Pharma, Pharma News, Pharmaceutical, Red Cross, Schering, Statins, tagged Crestor, Galvus, Merck, Novartis, Tasigna, Vioxx on November 9, 2007 | No Comments »
A huge week for news, especially on the cardiovascular front:
Prasugrel, the Lilly/Daiichi-Sankyo blood thinner, was the biggest headline grabber. This potential blockbuster came in with mixed results - good efficacy, but troubling side effects with some patients. Meanwhile, a bit further back in the pipeline, Schering-Plough’s experimental anti-clotting med continues to look very promising.
Speaking of [...]
Read Full Post »
Posted in Amylin, Avandia, Bayer, Biotech, GSK, Genentech, Genzyme, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Medical Devices, Merck, News, Novartis, Pharma, Pharma News, Pharmaceutical, Wyeth, tagged Avandia, Boston Scientific, Byetta, Doribax, Exubera, InVentiv Health, Isentress, Ixempra, Januvia, Lexiva on October 19, 2007 | 2 Comments »
The Good Stuff:
BMS gets approval for new oncology drug (for breast cancer) Ixempra.
Merck gets new HIV drug (Isentress) approved in the U.S. And, their Januvia diabetes drug gets new uses approved.
Abraxis gets cancer drugs approved.
J&J gets Doribax (for intra-abdominal and urinary tract infections) approved.
Bayer reports upbeat MS drug results.
Glaxo: new use of HIV drug Lexiva [...]
Read Full Post »
Posted in Allergan, Bayer, Celgene, Genzyme, News, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical, Takeda on September 21, 2007 | 1 Comment »
A summary of the belt-tightening state of Big Pharma right now, from Med Ad News.
From ABC, Ten Health Advances that have changed the world.
Americans trust the FDA more than pharma companies.
Pfizer’s new anti-smoking pill (Chantix) taking off.
Bayer and Genzyme get expanded labelling for oncology drug Campath.
Celgene reports great financial results due to sales of blood [...]
Read Full Post »
Posted in Amgen, Bayer, J&J, Johnson and Johnson, Medicine, Merck, Novartis, Pharma, Pharma News, Pharmaceutical, Roche, Sanofi-Aventis, Schering, Takeda on August 30, 2007 | No Comments »
On the Oncology front…
Bayer’s Nexavar shows encouraging results: Bayer and Onyx Pharmaceuticals said they were stopping a late clinical liver cancer trial with Nexavar in the Asia-Pacific region so patients can get the drug sooner after encouraging results…more
Vaccinating against other cancers? Should boys get the vaccine that prevents cervical cancer in women? Maybe, a new [...]
Read Full Post »
Posted in Abbott, BMS, Bayer, Merck, News, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Takeda on July 13, 2007 | 1 Comment »
Merck investing even more in its cancer portfolio - a growing trend among the top pharma companies.
Takeda seeking to grow its Amitiza franchise, now that Novartis’ Zelnorm has been pulled from the market.
Novartis gets approval for patch version of its Alzheimer’s drug Exelon.
More encouragement on the anti-blood-clotting front - BMS/Pfizer experimental drug apixaban meets goals [...]
Read Full Post »
Posted in AstraZeneca, Avandia, BMS, Bayer, Cephalon, GSK, Glaxosmithkline, J&J, Lilly, Merck, News, Novartis, Pfizer, Pharma News, Pharmaceutical, Scandal, Schering, Takeda on June 29, 2007 | No Comments »
Some robust pipelines: Glaxo Oncology, and J&J.
Cephalon moving more rapidly on oncology candidate Treanda.
Glaxo’s cervical cancer vaccine Cervarix looking good.
Byetta, a diabetes drug from Amylin and Lilly, shows solid results after 3 years of usage.
More good press for Actos, Takeda’s competitor to Avandia.
Cholesterol agents acting against diabetic nerve pain?
Two-pronged approach to treating diabetes - the [...]
Read Full Post »
Posted in Avandia, BMS, Bayer, Biotech, Celgene, Cephalon, Genentech, Glaxosmithkline, J&J, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical on June 8, 2007 | No Comments »
An Oncology News-fest, during ASCO week:
Genentech’s Avastin shown to be helpful for kidney cancer.
Bayer/Onyx’s Nexavar shows hopeful activity for liver cancer.
Pfizer’s still-experimental axitinib shows hopeful results with advanced thyroid cancer.
Sprycel creeping up on Gleevec as a potential first line treatment for leukemia.
Bristol’s experimental drug derived from African soil may delay progression of advanced breast cancer.
A [...]
Read Full Post »
